32 days
Submission to first decision

Pediatric Drugs promotes the optimization and advancement of all aspects of pharmacotherapy for healthcare professionals interested in pediatric drug therapy (including vaccines). The program of review and original research articles provides healthcare decision makers with clinically applicable knowledge on issues relevant to drug therapy in all areas of neonatology and the care of children and adolescents. The Journal includes:
overviews of contentious or emerging issues.
comprehensive narrative reviews of topics relating to the effective and safe management of drug therapy through all stages of pediatric development.
practical reviews covering optimum drug management of specific clinical situations.
systematic reviews that collate empirical evidence to answer a specific research question, using explicit, systematic methods as outlined by the PRISMA statement.
Adis Drug Reviews of the properties and place in therapy of both newer and established drugs in the pediatric population.
original research articles reporting the results of well-designed studies with a strong link to clinical practice, such as clinical pharmacodynamic and pharmacokinetic studies, clinical trials, meta-analyses, outcomes research, and pharmacoeconomic and pharmacoepidemiological studies.
Additional enhanced features (including slide sets, videos and animations) can be published with articles; these are designed to increase the visibility, readership and educational value of the journal’s content. In addition, articles published in Pediatric Drugs may be accompanied by plain language summaries to assist readers in understanding important medical advances.
All manuscripts are subject to peer review by international experts. Letters to the Editor are welcomed and will be considered for publication.

Editor (Adis International Limited, Auckland, New Zealand):
Rod McNab
Section Editors (Adis International Limited, Auckland, New Zealand):
Martin Chopra
Alison Fitches
Kathy Fraser
Kate Palmer
Dene Peters
Sue Pochon
Amitabh Prakash
David Williamson
Editorial Board:
Dermatology
R. Sidbury, Seattle Children's Hospital and University of Washington School of Medicine, Seattle, WA, USA
Drug Safety

C. Ferrajolo, University of Campania “Vanvitelli”, Napoli, Italy 

D. Kunac, University of Otago, Dunedin, New Zealand
I.C.K. Wong, University College London, London, England
Endocrinology
J. Hamilton-Shield, Bristol Royal Hospital for Children, Bristol, England
Gastroenterology
M. Aloi, Sapienza University of Rome, Rome, Italy
D.A. Gremse, University of South Alabama, Mobile, AL, USA
Infectious Diseases
S.L. Block, Kentucky Pediatric and Adult Research, Bardstown, KY, USA
B. Eley, Red Cross Children’s Hospital, Cape Town, South Africa
S. Esposito, Università degli Studi di Milano, Milan, Italy
J.E Girotto, Universityof Connecticut, Hartford, CT, USA
A.H. Groll, Children’s University Hospital, Münster, Germany
S.A. Halperin, Dalhousie University IWK Health Centre, Halifax, NS, Canada
T. Nolan, Murdoch Children's Research Institute, Parkville, VIC, Australia
M.E. Pichichero, Rochester General Hospital Research Institute, Rochester, NY, USA
E. Roilides, University of Thessaloniki, Thessaloniki, Greece
Intensive Care/Pain/Anesthesiology
J. Berkenbosch, University of Louisville, Louisville, KY, USA
S.N. de Wildt, Erasmus Medical Center-Sophia Children’s Hospital, Rotterdam, the Netherlands
W.M. Splinter, Children’s Hospital Eastern Ontario, Ottawa, ON, Canada
Neonatology
H. Walti, Université de Sherbrooke, Sherbrooke, QC, Canada
Neurology/Psychiatry
F.M.C Besag, East London Foundation NHS Trust, London, UK
R.L. Findling, The Johns Hopkins Hospital, Baltimore, MD, USA
G.L. Holmes, University of Vermont College of Medicine, Burlington, VT, USA
K.D Wagner, University of Texas Medical Branch, Galveston, TX, USA
Oncology/Hematology
L.L. Dupuis, The Hospital for Sick Children, Toronto, ON, Canada
S. Lowis, Bristol Royal Hospital for Children, Bristol, England
C.M. Zwaan, Erasmus Medical Center-Sophia Children’s Hospital, Rotterdam, the Netherlands
Pharmacology
G.L. Kearns, Paradise Valley, AZ, USA
S.M. MacLeod, University of British Columbia, Vancouver, BC, Canada
A. Neubert, University Hospital Erlangen, Erlangen, Germany
C.M.T. Sherwin, Wright State University Boonshoft School of Medicine, Dayton, OH, USA
J.N. van den Anker, Children’s National Health System, Washington, DC, USA, and University Children’s Hospital, Basel, Switzerland
D.A. van Riet-Nales, Medicines Evaluation Board, Utrecht, the Netherlands
Respiratory Medicine
A. Bush, Royal Brompton Hospital, London, England
D. Fitzgerald, Children’s Hospital at Westmead, Westmead, NSW, Australia
Rheumatology/Immunology
R. Cimaz, University of Milan, Milan, Italy
D. B. Horton, Rutgers Biomedical and Health Sciences, New Brunswick, NJ, USA